# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(1.04) by ...
Cipla to take sole responsibility for development of PUR1900, refocused on markets with greatest unmet need and faster path to ...
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(1.03) per share which beat the analyst consensus estimate of $(1.05) by ...
On Wednesday, 311 stocks hit new 52-week lows.
On Tuesday, 386 stocks made new 52-week lows.
Pulmatrix received a study may proceed letter for a Phase 2 Study to Evaluate PUR3100, an orally inhaled dry powder formulation...
Friday's session saw 225 companies set new 52-week lows.
On Wednesday, 59 companies achieved new lows for the year.